| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0001 |
| mRNA | BRD6340 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0003 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0005 |
| mRNA | SJ-172550 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0005 |
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.15 | 0.0007 |
| mRNA | tivozanib | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0008 |
| mRNA | BRD-K70511574 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | FQI-2 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |